News Search Results
Feb 24, 2026, 16:01 ET AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 24, 2026, 13:09 ET Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals
Feb 24, 2026, 10:08 ET Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing
continuity."The collaboration will support a broad range of applications, including investigational cell therapies and platform technologies across biotechnology, pharmaceutical, and government-sponsored programs. Both companies will continue operating independently while collaborating to support shared clients.About
More news about: Cellipont Bioservices
Feb 24, 2026, 10:00 ET Particles for Humanity Announces Publication Demonstrating Breakthrough in Vitamin A Stability for Food Fortification
CAMBRIDGE, Mass., Feb. 24, 2026 /PRNewswire/ -- Particles for Humanity, a mission-driven biotechnology company developing nutrition technologies for low- and middle-income countries, today announced the publication of new data in
More news about: Particles for Humanity
Feb 24, 2026, 10:00 ET Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1
patients, the ketogenic diet can be challenging to maintain long term.About Bloom ScienceBloom Science is a clinical-stage biotechnology company developing new therapies for neurological disorders and metabolic diseases, including obesity. Rooted in gut-brain axis biology and microbiome
More news about: Bloom Science, Inc.
Feb 24, 2026, 09:35 ET Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
https://www.financialnewsmedia.com/news-help/Latest Biotech Drugs Attracting Interest may also include:Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,
More news about: Market News Updates
Feb 24, 2026, 09:00 ET Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the appointment of Blake Arnold, CFA, as Chief Business
More news about: Kenai Therapeutics/BIOCOM
Feb 24, 2026, 09:00 ET BioMarin to Participate in Four Upcoming Investor Conferences in March
Company's website for a limited time following the conferences.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
care, orthobiologics, and regenerative medicine, is pleased to announce a transformative investment and strategic partnership with Jellagen Ltd, the UK-based biotechnology innovator pioneering Collagen Type Zero: a next-generation, jellyfish-derived, sustainable biomaterial.
More news about: Royal Biologics
Feb 24, 2026, 09:00 ET Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
equity restructuring. The shares previously held by Haier Financial Holdings have been formally acquired by existing shareholder Shanghai Liferiver Biotechnology Co., Ltd. ("Liferiver Biotech") and new strategic investor Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. ("Yanghe Investment").
More news about: Sanyou Bio
Feb 24, 2026, 09:00 ET Accelerated Engineering Software and Certified Composite Production Capturing Share of $100B+ Aerospace Market
the development of next-generation biotechnology and materials science under the Functional Responsive Experimentation for Systems and Humans (FRESH) program at Wright Patterson Air Force Base in Dayton, Ohio.Under Task Order 0003 (TO-03), titled "Biotechnology and Biomaterials and Polymers and
More news about: Market News Updates
Feb 24, 2026, 08:50 ET Draper and Partners Awarded ARPA-H Funding to Develop New In Silico Models of Human Physiology for Drug Development
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
technologiesSAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company pioneering programmable RNA medicines, today announced the appointment of Devyn Smith, Ph.D., as an independent member of its Board of Directors,
More news about: Therna Biosciences
Feb 24, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
replay for 90 days after the call via the Rigel website.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026
K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced data from its Phase 1 clinical trial of KTX-2001
More news about: K36 Therapeutics
Feb 24, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Tax Certificate Transfer Program (NOL Program)The Technology Business Tax Certificate Transfer Program enables approved technology and biotechnology businesses with net operating losses to sell their unused net operating loss carryover (NOL) and unused research and development tax credits (R&D
More news about: Citius Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
developing DNA methylation and other bead-based genomics assays in addition to NGS structural variant informatics. Illumina, Inc. is a leading American biotechnology company headquartered in San Diego, specializing in the development, manufacturing, and marketing of integrated systems for large-scale analysis
More news about: Klotho Neurosciences, Inc.
Feb 24, 2026, 07:30 ET Soligenix to Present at BIO Investment & Growth Summit
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Feb 24, 2026, 07:00 ET ERS Genomics launches new Early Access Express License
immune defence system, CRISPR/Cas9 is a precise, efficient tool for editing DNA in living organisms that has transformed research across genetics, biotechnology, and molecular biology.ERS Genomics offers non-exclusive licenses to the CVC Patents for research and commercial applications outside the
More news about: ERS Genomics
Feb 24, 2026, 07:00 ET Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Feb 24, 2026, 03:42 ET ArisGlobal Launches XDI
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 24, 2026, 03:32 ET ArisGlobal Launches XDI
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 24, 2026, 02:50 ET BPC Instruments receives two repeat orders from Denmark within biogas applications
(publ)BPC Instruments is a Swedish technology company developing analytical instruments for renewable bioenergy and environmental biotechnology, including biogas and biodegradability testing. The systems enable advanced testing with higher accuracy and consistency, while reducing the time
More news about: BPC Instruments AB
Feb 23, 2026, 17:30 ET Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Feb 23, 2026, 17:00 ET Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
responsible for 60% and Vir Biotechnology responsible for 40% of all costs. Vir Biotechnology will continue the ongoing Phase 1 trial, until responsibility is transitioned to Astellas, after which Astellas will be responsible for all development activities. In the U.S., Vir Biotechnology will have the option
More news about: Astellas Pharma Inc.